Get started
EOLUS VIND (EOUL_B) | Renewable Energy From SwedenHi, Eolus Vind AB (publ) primarily engages in the development, establishment, and operation of facilities for renewable energy and energy storage in the Nordic region, Sweden, Norway, Finland, Baltic countries, and the United States. The company operates through three segments: Project Development, Asset Management, and Electricity Generation. It engages in the operation of wind turbines; production and sale of electricity; and sale of electricity certificates. The company is also involved in the pre-study, project development, and establishment of wind power facilities. If you have faith in renewable energy and wind power then this might be your chance. Technically, I can see that the long-term growing "platform" is pretty solid, it stays between 170-200 SEK. Do your own research about fundamentals, company potential, valuation numbers and etc. Do not forget that the perfect investment decision consists of good fundamentals (you have to make your own research) and you need a good buying area (you have it)! Stay healthy, Vaido
OMXSTO:EOLU_BLong
by VaidoVeek
2
SWED strong support at 140, potential to bullish 160The three lines indicate previous support or resistance levels. Swedbank recently broke the 160 resistance but quickly dipped. The breaking of 150 indicates to me that it will continue down towards 140 where it will find strong support. Watch out for bullish candle signals as it closes the gaps to 140. SWED will probalby bullish to 150 and if it breaks the resistance it will most likely continue to 160 where it would be wise to start thinking about securing profits. The current trading candles show a somewhat indecisive market and thus I do not believe that it will break above 150, but anything can happen. Anything you notice that i might have missed? Please comment! Do not take this as blind investment advice. Do your own research before investing!
OMXSTO:SWED_ALong
by Felixfnm
Intervacc caseThe vaccine candidate/product Intervaccs vaccine candidate for horses is on time and responses to EMA DAY 120 questions have been submitted regarding the Company's Marketing Authorization on 12 january this year. Application (MAA) for Strangvac has been submitted on this day to the European Medicines Agency (EMA). Intervacc is seeking approval for Strangvac as a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Decision expected in (early?) Q2 this year. After validating the submission and reviewing the responses, a second list of questions and outstanding issues is expected from the Committee for Medicinal Products for Veterinary Use (CVMP). The Company estimates that it is on track for a positive opinion from the CVMP during Q2 2021. The vaccine has been developed with an innovative technology and is based on recombinant fusion proteins. The research behind the vaccine's technical platform has been done together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU. The MAA for Strangvac is based on a successful series of clinical studies demonstrating the safety, immunogenicity, efficacy and DIVA capability of this exciting vaccine. DIVA (Differentiation of Infected from Vaccinated Animals) capability is a key feature for prevalent endemic diseases such as equine strangles in order to distinguish vaccinated animals from those that have been exposed to the bacteria Streptococcus equi Business model I believe the business rollout/model going through existing vaccine programmes has a lot of potential to be succesfull. I also belive there is a high probability the vaccine will go through. The company have been working on this for 16 years, it's not like the covid vaccine. Today there is no good solution for the very dangerous and costly decease. The whole stable will need to be put into quarantine if one horse is infected. I believe insurance companies will more or less demand that insured horses and stables take the vaccine. Pricing believed to be around 300 kr per vaccine. 2-3 needed first year and then refills. Gross margins above 90%. Modelling value and price doses - there are 60 million horses in the world. The company calculate with 20 million in their target area, Europe, US, Australia and the Mid East. Intervaccs graph suggest around 16-17 million horses within main area with 6 million in their first market Europe, and 10 million in the second, the US, as well as 1 million in Australia. The US rollout can be expected first in second part of 2021. - 30-60% meets vets and are in vaccination programs - Intervacc recommend 2-3 doses per year, CEO calculates with around 1,5 dose per year - Intervacc suggest the first doses will work for "at least 12 months" in their presentation. - some known investors in Sweden believe there's a need for 3 doses the first year price - 100 kr for vaccine against influenca - the comapany as well as investors had early estimates of around 120 kr (in 2018) - but in 2020 the CEO says he believe they can set a price of 300 kr (september 2020) per dose and he believes the customers are willing to pay this price. my napking sketch - year 2021–2023: 7,5 million horses x 35% x 1-1,5 dose = 2,6–3,9 million doses per year x a price of 200 kr/dose: 520–780 miljoner kr/year - year 2024–2025: 15 million horses x 45% x 1-1,5 dose = 6,8–10,1 million doses per year x price of 230 kr/dos: 1 564–2 323 million kr/year* *I actually have come to believe the 300 kr per dose is a good price and perhaps there will be a faster rollout than calculated. However you look at it, enterprise value, given the vaccine is approved and that business model and price has a product market fit, coudl or should have a very nice expansion. I expected an upside between 2-3x in 2020-09-13 but now I've come to expect an 2,5 x upside from here, not counting optionality. Enterprise value per 2020-09-13: 1,76 billion kr (at time of napkin sketch) Enterpise value per today 2021-01-29: 2,54 billion kr Technical Looking for breakout above 52, cheat, followed with interest points at 54,5 and later 58.
ILong
by kulturdesken
RakeTech in upward trendRakeTech will likely follow an upwards short-term trend. Be aware that RakeTech has a low volume and small market Cap, making it rather risky. The stock has experienced a golden cross in August 2020, and has been climbing nicely in the trend channel since. Shortly in November the upper bound was tested, and the price lowered to the limit of the lower bound. This movement was resisted by a support level in 10.30. The price is now heading towards the price gap experienced in November 2019, with a rising RSI, whereby the price might break above 11.85 and go for 13.05.
RLong
by PersonalFinanceDude